Pfizer (PFE) Total Debt (2009 - 2026)

Pfizer (PFE) has 18 years of Total Debt data on file, last reported at $64.5 billion in Q1 2026.

• Total Debt for Q1 2026 came in at $64.5 billion, up 3.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.5 billion (up 3.78% YoY), and the FY2025 annual result was $64.8 billion, up 1.33% from the prior year.
• Total Debt retreated to $64.5 billion in Q1 2026 per PFE's latest filing, from $64.8 billion in the prior quarter.
• Over five years, Total Debt peaked at $71.9 billion in Q4 2023 and troughed at $35.8 billion in Q4 2022.
• A 5-year average of $57.1 billion and a median of $63.6 billion in 2023 frame the typical range for Total Debt.
• The sharpest annual moves came in 2023 and 2024: Total Debt surged 100.64% in 2023, then slipped 11.05% in 2024.
• A 5-year view of Total Debt shows it stood at $35.8 billion in 2022, then surged by 100.64% to $71.9 billion in 2023, then fell by 11.05% to $63.9 billion in 2024, then advanced by 1.33% to $64.8 billion in 2025, then fell by 0.52% to $64.5 billion in 2026.
• Business Quant data shows PFE's Total Debt at $64.5 billion in Q1 2026, $64.8 billion in Q4 2025, and $61.7 billion in Q3 2025.